IOVA — Iovance Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00- $3.25bn
- $2.97bn
- $1.19m
Annual income statement for Iovance Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 1.19 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | -9.57 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 207 | 262 | 343 | 399 | 462 |
| Operating Profit | -207 | -262 | -343 | -399 | -461 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -198 | -260 | -342 | -396 | -448 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -198 | -260 | -342 | -396 | -444 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -198 | -260 | -342 | -396 | -444 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -198 | -260 | -342 | -396 | -444 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.59 | -1.87 | -2.23 | -2.49 | -1.89 |